(S-101) A Population Pharmacokinetic Approach to Prospectively Assess Vancomycin Pharmacokinetics in Adult Jordanian Patients: a Step towards Personalized Dosing
Post doc Indiana University Indianapolis, Indiana, United States
Disclosure(s):
Malek Hajjawi, PharmD: No financial relationships to disclose
Enter your core abstract text here using the suggested layout. Abstracts are text only: No figures/tables. Do not paste author or affiliation information in the body of your abstract. Max character count not including spaces for abstract body is 2800.:
Background: Vancomycin is a glycopeptide antibiotic that is frequently used to treat severe gram-positive bacterial infections, particularly, methicillin-resistant Staphylococcus aureus (MRSA) infections (1). Being a highly variable drug with a narrow therapeutic window (2,3), personalized dosing strategies are required to maximize efficacy and minimize toxicity (4).
Objectives: In this study, we aimed to develop a population pharmacokinetic (PopPK) model for Vancomycin utilizing data obtained from the University of Jordan Hospital, additionally to identify significant covariates that affect vancomycin disposition for implementing personalized dosing regimens.
Method: Vancomycin serum concentrations were collected prospectively from patients who are 18 years or older. Demographic data such age and weight alongside relevant renal function tests were also collected. Population pharmacokinetic model was established using nlmixr2 with one-compartment model as the structural model. Pharmacokinetic parameters were analyzed for influence given the following potential covariates: weight (WT); age (AGE); estimated glomerular filtration rate (EGFR); and albumin (ALB). Model validation was performed, and the final model was used to personalize vancomycin therapy with the goal of reaching target concentrations of 10-20 μg/mL.
Results: The derived model sufficiently described the pharmacokinetics of vancomycin demonstrated by a total clearance (CL) of 0.333 L/h (95% CI: 0.210-0.528) and volume of distribution (V) of 175.09 L (95% CI: 138.812-216.891). between-subject variability was for clearance (CV=12.4%) and moderate for volume of distribution (CV=33.19%). Among the investigated covariates, EGFR had a significant effect on clearance (coefficient=0.536, 95% CI: 0.097 -0.975)8; neither weight effect on volume of distribution nor clearance was statistically significant. We found both a proportional (0.107) and an additive (6.046 μg/mL) component to the residual error model.
Conclusion: This study showed that a population pharmacokinetic approach can accurately describe vancomycin disposition in patients at the University of Jordan Hospital, with renal function (EGFR) identified as the most important covariate of vancomycin clearance. The model developed should be useful for individualizing vancomycin dosing regimens to attain target therapeutic concentrations of 10-20 μg/mL, possibly leading to better treatment outcomes with fewer adverse effects.
Citations: 1. Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864. 2. Vandecasteele SJ, et al. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother. 2013;68(4):743-748. 3. Wei S, et al. Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients. Front Pharmacol. 2022;13:1005791. 4. He N, et al. The Benefit of Individualized Vancomycin Dosing Via Pharmacokinetic Tools: A Systematic Review and Meta-analysis. Ann Pharmacother. 2020;54(4):349-355. 5. Mena M, et al. Implementing Vancomycin Population Pharmacokinetic Models: An App for Individualized Antibiotic Therapy in Critically Ill Patients. Antibiotics. 2023;12(2):301.
